Vimpat

(Lacosamide)

ApprovedSmall molecule

Lacosamide is used to treat epilepsy and seizures. It can be used alone or combined with other seizure medications to help control partial-onset seizures.[2] Vimpat is currently approved and in use across 19 indications[4].[1]

Vimpat is one of 370 small molecule programs targeting Postherpetic Neuralgia. It is currently in Approved.

Indications

Total Trials

Active Trials

369

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

Postherpetic NeuralgiaApproved

Migraine DisorderApproved

SeizureCompleted

Brain NeoplasmApproved

Kidney DiseaseApproved

ParagangliomaApproved

Amyotrophic Lateral SclerosisApproved

Alcohol DependenceApproved

Malignant GliomaActive, not recruiting

ConvulsionActive, not recruiting

Postherpetic NeuralgiaApproved

Approved

Migraine DisorderApproved

Approved

SeizureApproved

Completed

Brain NeoplasmApproved

Approved

Kidney DiseaseApproved

Approved

ParagangliomaApproved

Approved

Amyotrophic Lateral SclerosisApproved

Approved

Alcohol DependenceApproved

Approved

Malignant GliomaPreclinical

Active, not recruiting

ConvulsionApproved

Active, not recruiting

Showing 10 of 19 indications

Competition

Competitive Landscape

105 competitors in Kidney Disease

#DrugCompanyPhaseTrials

Vimpat

UCB

Approved

91 2

Farxiga

AstraZeneca

Approved

4 3

Sensipar

Amgen

Approved

2 4

Jardiance

Boehringer Ingelheim

Approved

6 5

Aubagio

Opzelura

Neoral

Norvir

Tafinlar

Myrbetriq

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 3Recruiting

Major Depressive Episode

NCT07412132

Q2 2027

Post-ApprovalRecruiting

Brain Injury

NCT06866691

Q4 2027

Not yet recruiting

Status Epilepticus

NCT06966830

Recruiting

Trigeminal Neuralgia

NCT06851910

Clinical

Trials by Indication[1]

Seizure23 trials

Determine Safety and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures

Completed· UCB logo

UCB·Phase 3·NCT00522275·308 enrolled

To Determine Tolerability and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures

Completed· UCB logo

UCB·Phase 2·NCT00552305·370 enrolled

Trial to Assess Long-term Lacosamide (LCM) Monotherapy Use and Safety of LCM Monotherapy and Adjunctive Therapy for Partial-onset Seizures

Completed· UCB logo

UCB·Phase 3·NCT00530855·322 enrolled

Show 20 more trials

A Trial to Evaluate the Long Term Safety and Tolerability of Lacosamide Taken as Monotherapy in Adults With Partial-onset Seizures

Completed· UCB logo

UCB·Phase 3·NCT02124564·19 enrolled

Trial to Assess Lacosamide as the First add-on Anti-epileptic Drug Treatment in Patients With Partial-onset Seizures

Completed· UCB logo

UCB·Phase 4·NCT00955357·461 enrolled

Study to Evaluate the Safety, Tolerability, and Efficacy of Long-term Adjunctive Therapy With Lacosamide in Adults With Partial-onset Seizures

Completed· UCB logo

UCB·Phase 3·NCT01832038·473 enrolled

A Multicenter, Open-Label Study To Investigate The Safety And Pharmacokinetics Of Lacosamide In Children With Partial Seizures

Completed· UCB logo

UCB·Phase 2·NCT00938431·47 enrolled

Safety of Intravenous Lacosamide Dose Followed by Twice Daily Oral Lacosamide in Subjects With Partial-onset Seizures

Completed· UCB logo

UCB·Phase 3·NCT00655551·100 enrolled

Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects ≥1 Month to <4 Years With Partial-onset Seizures

Completed· UCB logo

UCB·Phase 3·NCT02477839·255 enrolled

A Trial to Evaluate the Efficacy and Safety of Adjunctive Therapy With Lacosamide in Adults With Partial-Onset Seizures

Completed· UCB logo

UCB·Phase 3·NCT01710657·548 enrolled

Open-label Study to Evaluate the Safety and Tolerability of iv Lacosamide in Japanese Adults With Partial-onset Seizures

Completed· UCB logo

UCB·Phase 3·NCT02192814·9 enrolled

Safety and Efficacy of Lacosamide as Additional Therapy in Patients Suffering From Epileptic Tonic-Clonic Seizures

Completed· UCB logo

UCB·Phase 3·NCT02408549·239 enrolled

Assess Safety and Efficacy of Lacosamide in Patients With Partial Seizures

Completed· UCB logo

UCB·Phase 3·NCT00515619·376 enrolled

Study Evaluating Changes in Total Drug Load and Seizure Frequency Using Vimpat® (Lacosamide) in Combination Therapy

Completed· UCB logo

UCB··NCT01673282·315 enrolled

Trial to Assess Optimized Dosage of Lacosamide as add-on Therapy in Patients With Partial Onset Seizure

Completed· UCB logo

UCB·Phase 4·NCT01235403·100 enrolled

Trial to Demonstrate the Efficacy and Safety of Conversion to Lacosamide Monotherapy for Partial-onset Seizures

Completed· UCB logo

UCB·Phase 3·NCT00520741·426 enrolled

Post-Authorization Safety Study to Assess the Safety of Vimpat as add-on Therapy in Patients With Partial-onset Seizures

Completed· UCB logo

UCB··NCT00771927·1,005 enrolled

Compassionate Use Program With Lacosamide in Patients With Partial-onset or Generalized Tonic-clonic Seizures

No longer available· UCB logo

UCB··NCT03559673

A Pilot Study of NSICU Assessment of Seizure Prophylaxis With Lacosamide

Terminated·UUniversity of Alabama at Birmingham·N/A·NCT01110187·11 enrolled

Comparative Trial of IV Lacosamide Versus Phenytoin for Seizure Management

Terminated·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·Phase 4·NCT02409433·3 enrolled

Study to Investigate Lacosamide as Add-on Therapy in Subjects ≥4 Years to <17 Years of Age With Partial Onset Seizures

Completed· UCB logo

UCB·Phase 3·NCT01921205·404 enrolled

Belgian Drug-utilization Study to Evaluate the Use of VIMPAT® as Adjunctive Treatment of Partial Onset Seizures in Subjects Aged 16 and Older

Completed· UCB logo

UCB··NCT01236001·192 enrolled

Study to Assess the Long-term Safety of Oral Lacosamide in Subjects With Partial-onset Seizures

Completed· UCB logo

UCB·Phase 3·NCT00655486·97 enrolled

Epilepsy11 trials

An Open-Label Study to Determine Safety , Tolerability, and Efficacy of Oral Lacosamide in Children With Epilepsy

Completed· UCB logo

UCB·Phase 2·NCT00938912·366 enrolled

Open-Label Study to Assess Lacosamide Safety as Add-on Therapy for Primary Generalized Tonic-Clonic Seizures in Subjects With Epilepsy

Completed· UCB logo

UCB·Phase 2·NCT01118949·49 enrolled

Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older

Completed· UCB logo

UCB·Phase 3·NCT01243177·888 enrolled

Show 8 more trials

A Clinical Study to Investigate the Efficacy and Safety of Lacosamide as an Add on Therapy in Children With Epilepsy With Partial-onset Seizures

Completed· UCB logo

UCB·Phase 3·NCT01964560·540 enrolled

A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications

Completed· UCB logo

UCB·Phase 3·NCT02408523·242 enrolled

Improvement Effect of Lacosamide and Levetiracetam on Cognitive in Alzheimer's Disease Patients With Epilepsy

Unknown status·XXiangya Hospital of Central South University·Phase 4·NCT05969054·140 enrolled

Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older

Completed· UCB logo

UCB·Phase 3·NCT01465997·551 enrolled

Evaluation of the Efficacy and Safety of Lacosamide in Pediatric Patients With Epilepsy

Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 4·NCT04144218·300 enrolled

Open-Label Extension Study to Assess the Safety and Seizure Frequency Associated With Lacosamide for Primary Generalized Tonic-Clonic Seizures in Subjects With Epilepsy

Completed· UCB logo

UCB·Phase 2·NCT01118962·39 enrolled

A Real World Study on the Efficacy and Safety of Lacosamide as Add-on Therapy for Focal-onset Epilepsy

Unknown status·JJiangxi Qingfeng Pharmaceutical Co. Ltd.··NCT04737837·200 enrolled

Randomized Controlled Trial to Assess Effects of Lacosamide on Sleep and Wake in Adults With Focal Epilepsy

Completed·TThe Cleveland Clinic·Phase 4·NCT01190098·59 enrolled

Migraine4 trials

A Study Designed to Test the Effectiveness and Safety of Treating Patients With Lacosamide for Migraine Prophylaxis

Completed· UCB logo

UCB·Phase 2·NCT00440518·218 enrolled

Lacosamide Versus Propranolol in Migraine

Completed·KKafrelsheikh University·Phase 3·NCT05851781·600 enrolled

The Lacosamide's Effect on Calcitonin Gene-related Peptide in Migraine Patients

Completed·KKafrelsheikh University·Phase 3·NCT05632133·200 enrolled

Show 1 more trial

Lacosamide Versus Topiramate in Migraine

Recruiting·KKafrelsheikh University·Phase 3·NCT06243692·600 enrolled

Status Epilepticus3 trials

Lacosamide in Neonatal Status Epilepticus

Unknown status·SSherief Abd-Elsalam·Phase 3·NCT05291455·60 enrolled

Lacosamide Intravenous Injection for Emergency Termination of Status Epilepticus

Not yet recruiting·SSecond Affiliated Hospital of Guangzhou Medical University··NCT06966830·100 enrolled

Levetiracetam, Lacosamide and Ketamine as Adjunctive Treatment of Refractory Status Epilepticus

Withdrawn·MMid-Atlantic Epilepsy and Sleep Center, LLC·Phase 3·NCT02726867

Intravenous3 trials

Study to Investigate Safety and Tolerability of Intravenous Lacosamide in Children.

Completed· UCB logo

UCB·Phase 2/3·NCT02710890·103 enrolled

A Study to Investigate the Bioequivalence of Lacosamide 200mg Administered as Intravenous Solution and Oral Tablet in Healthy Chinese Male Subjects

Completed· UCB logo

UCB·Phase 1·NCT03204474·30 enrolled

The Safety of Intravenous Lacosamide

Completed·LLe Bonheur Children's Hospital·Phase 4·NCT00832884·40 enrolled

39 more indications

Diabetic Neuropathy3 trials

A Follow-On Trial to Assess the Long Term Safety and Efficacy of SPM 927 in Painful Distal Diabetic Neuropathy

Completed· UCB logo

UCB·Phase 2/3·NCT00235443·451 enrolled

A Trial to Assess the Long-term Safety and Efficacy of Lacosamide in Subjects With Painful Diabetic Neuropathy

Completed· UCB logo

UCB·Phase 3·NCT00220337·371 enrolled

Study Evaluating Long-term Safety and Efficacy of Lacosamide in Subjects With Painful Distal Diabetic Neuropathy.

Completed· UCB logo

UCB·Phase 3·NCT00546351·621 enrolled

CAR2 trials

Hormonal and Lipid Levels in Male Subjects After a Switch From Carbamazepine to Lacosamide

Terminated· UCB logo

UCB·Phase 3·NCT01375374·11 enrolled

Crossover Study of Neuropsychological Effects of Lacosamide and Carbamazepine Immediate Release in Healthy Subjects

Completed· UCB logo

UCB·Phase 1·NCT01530022·60 enrolled

Neuropathic Pain2 trials

The Effect of Lacosamide in Peripheral Neuropathic Pain

Terminated·—·Phase 2·NCT03777956·63 enrolled

An Open-label Continuation Trial to Assess the Continued Efficacy and Safety of Ascending Doses of Lacosamide in Subjects With Chronic Refractory Neuropathic Pain

Completed· UCB logo

UCB·Phase 2·NCT00237458·7 enrolled

Monotherapy2 trials

A Clinical Study to Investigate the Long-term Use of Lacosamide as Monotherapy in Subjects Who Completed Study SP0994

Completed· UCB logo

UCB·Phase 3·NCT02582866·106 enrolled

Add on Lacosamide Versus High Dose Monotherapy

Completed·—·Phase 3·NCT01345058·56 enrolled

Brain Injury2 trials

Antiseizure Medication in Seizure Networks at Early Acute Brain Injury

Terminated·UUniversity of North Carolina, Chapel Hill·Phase 4·NCT06081283·5 enrolled

Seizure Prevention in Traumatic Brain Injury With Levetiracetam and Lacosamide

Recruiting·WWake Forest University Health Sciences·Phase 4·NCT06866691·600 enrolled

OSA2 trials

A Study to Demonstrate the Bioequivalence of Lacosamide Tablets and Dry Syrup in Healthy Male Japanese Subjects

Completed· UCB logo

UCB·Phase 1·NCT02972125·24 enrolled

A Study to Investigate the Bioequivalence of Lacosamide Tablet (200mg) and Syrup (10mg/ml) in Healthy Chinese Male Subjects

Completed· UCB logo

UCB·Phase 1·NCT03086382·24 enrolled

Tics2 trials

To Evaluate the Pharmacokinetics and Safety/Tolerability of Lacosamide in 3 Dosages in Healthy Male Korean Subjects

Completed· UCB logo

UCB·Phase 1·NCT01450111·51 enrolled

Three-way-cross-over Study to Evaluate Safety and Pharmacokinetics of Lacosamide in Healthy Japanese and Chinese Males

Completed· UCB logo

UCB·Phase 1·NCT01375387·33 enrolled

Chronic Pancreatitis1 trial

STTEPP: Safety, Tolerability and Dose Limiting Toxicity of Lacosamide in Patients With Painful Chronic Pancreatitis

Recruiting·IIndiana University·Phase 1·NCT05603702·24 enrolled

Fibromyalgia1 trial

Assessing Efficacy and Safety of Lacosamide Compared to Placebo in Reducing Signs and Symptoms of Fibromyalgia Syndrome.

Completed· UCB logo

UCB·Phase 2·NCT00401830·159 enrolled

Osteoarthritis1 trial

Trial to Assess Efficacy and Safety of Lacosamide in Subjects With Osteoarthritis of the Knee

Terminated· UCB logo

UCB·Phase 2·NCT00485472·194 enrolled

Epilepsy Syndrome1 trial

A Study to Investigate the Safety and Efficacy of Lacosamide Added to the Patients Current Therapy in Patients Aged 1 Month to Less Than 18 Years Old With Epilepsy Syndromes Associated With Generalized Seizures.

Completed· UCB logo

UCB·Phase 2·NCT01969851·55 enrolled

Neuropathy1 trial

Safety and Tolerability of Lacosamide in Patients With Gain-of-function Nav1.7 Mutations Related Small Fiber Neuropathy

Completed·AAcademisch Ziekenhuis Maastricht·Phase 3·NCT01911975·25 enrolled

Autoimmune Encephalitis1 trial

Acute Sympotomatic Seizure Secondary to Autoimmune Encephalitis and Autoimmune-associated Epilepsy

Unknown status·LLiu Yonghong··NCT05422664·500 enrolled

Partial Epilepsy1 trial

Systematic Review: Retigabine for Adjunctive Therapy in Partial Epilepsy

Completed· GSK logo

GSK··NCT01587339·6,498 enrolled

Epileptics1 trial

Pharmacokinetics of Antiepileptics in Patients on CRRT

Completed·UUniversity of Maryland, Baltimore··NCT03632915·18 enrolled

Pediatrics1 trial

Population Pharmacokinetics of Antiepileptic in Pediatrics

Completed·AAssistance Publique - Hôpitaux de Paris··NCT03196466·753 enrolled

EEG1 trial

Lacosamide IV and EEG/EKG (LIVE) Study

Terminated·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·Phase 2·NCT01724918·72 enrolled

Clinical Trial1 trial

Open-label Clinical Trial of Lacosamide in ALS

Completed·—·Phase 1/2·NCT03186040·7 enrolled

Metastasis1 trial

Seizure Prophylaxis in Patients With Glioma or Brain Metastasis

Terminated·—·Phase 2·NCT03436433·4 enrolled

Sciatica1 trial

COMPARISON OF EFFICACY OF DIFFERENT DRUG COMBINATIONS IN ACUTE SCIATICA

Completed·PPakistan Institute of Medical Sciences·Phase 3·NCT05626140·120 enrolled

Fasting Conditions1 trial

An Open Label, Balanced, Randomized, Two-Treatment, Two-Period, Two-Sequence, Two-way Crossover, Oralcomparative Pharmacokinetic（PK）Study of Lacosamide Extended-Release Tablets , Adult, Human Subjects Under Fasting Conditions.

Unknown status·OOverseas Pharmaceuticals, Ltd.·Phase 1·NCT05788159·16 enrolled

Alcohol Use Disorder (AUD)1 trial

Pilot Human Lab Study of Lacosamide in Alcohol Use Disorder (AUD)

Completed·UUniversity of California, San Francisco·Phase 2·NCT03897348·4 enrolled

Neonatal seizure1 trial

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Lacosamide in Neonates With Repeated Electroencephalographic Neonatal Seizures

Terminated· UCB logo

UCB·Phase 2·NCT04519645·29 enrolled

Renal Impairment1 trial

Study to Evaluate the Pharmacokinetics, Safety, Tolerability of Single Dose Lacosamide in Subjects With Renal Impairment Compared to Healthy Subjects

Completed· UCB logo

UCB·Phase 1·NCT01796938·40 enrolled

Infusion1 trial

Bioavailability/Bioequivalence Study Between Lacosamide Tablet and Solution for Infusion in Healthy Japanese Subjects

Completed· UCB logo

UCB·Phase 1·NCT01986608·26 enrolled

Pregabalin1 trial

Combined Effect of Pregabalin and Oxycodone, and Lacosamide and Oxycodone, on Breathing

Completed·LLeiden University Medical Center·Phase 4·NCT05598905·24 enrolled

Sleep1 trial

A Multicenter, Open-label Study to Determine the Effects of Lacosamide on Sleep in Healthy Subjects

Completed· UCB logo

UCB·Phase 1·NCT01530386·25 enrolled

Total Hip Arthroplasty1 trial

Effects of Lacosamide on Post-operative Opioid Requirements After a Total Hip Arthroplasty:

Withdrawn·IIndiana University School of Medicine·Phase 2·NCT02342977

Major Depressive Episode1 trial

Evaluation of the Efficacy, Safety, and Tolerability of Lacosamide in Major Depressive Episodes of Bipolar Disorder Types I and II.

Recruiting·UUniversity of Sao Paulo·Phase 3·NCT07412132·40 enrolled

Malignant Glioma1 trial

Lacosamide in Preventing Seizures in Participants With Malignant Glioma

Terminated·MM.D. Anderson Cancer Center·N/A·NCT01432171·37 enrolled

Oral1 trial

Cognitive and Behavioral Effects of Lacosamide

Completed·EEvan Fertig·Phase 4·NCT01175954·32 enrolled

Heavy Drinker1 trial

Lacosamide Effects on Alcohol Self Administration and Craving in Heavy Drinkers

Completed·—·Phase 1·NCT03271528·66 enrolled

Transcranial Magnetic Stimulation1 trial

Effects of Lacosamide on Human Motor Cortex Excitability: a Transcranial Magnetic Stimulation Study

Completed·UUniversity of Kiel·N/A·NCT01382017·18 enrolled

Medication1 trial

Observational Retrospective Study of Effectivity and Tolerability in Patients With Lacosamide Medication

Completed·IInstituto de Investigacion Sanitaria La Fe··NCT01858870·860 enrolled

Herpes Zoster1 trial

Comparative Efficacy of Pregabalin and Lacosamide in Patients With Herpes Zoster and Post Herpetic Neuralgia

Recruiting·—·N/A·NCT06969417·50 enrolled

Treatment1 trial

A Study to Test the Long-term Use of Oral Lacosamide in Pediatric Study Participants Who Completed NCT01964560 (EP0034) or NCT00938912 (SP848) and Received Lacosamide Treatment

Completed· UCB logo

UCB·Phase 3·NCT04627285·48 enrolled

Efficacy1 trial

eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam

Completed· UCB logo

UCB·Phase 3·NCT01484977·120 enrolled

Trigeminal Neuralgia1 trial

Intravenous Lacosamide for the Treatment of Acute Pain in Trigeminal Neuralgia: A Prospective Observational Study

Recruiting·HHospital Universitari de Bellvitge··NCT06851910·20 enrolled

Unspecified1 trial

Pharmacovigilance in Gerontopsychiatric Patients

Terminated·HHannover Medical School·Phase 3·NCT02374567·407 enrolled

Regulatory

FDA Approval Timeline[5]

Oct 28, 2008

VIMPAT

NDA NDA022254

Oct 28, 2008

VIMPAT

NDA NDA022253

Apr 20, 2010

VIMPAT

NDA NDA022255

May 4, 2023

MOTPOLY XR

NDA NDA216185

Sources

References

[1]
ClinicalTrials.gov — 91 trial records for Lacosamide. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Vimpat drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Lacosamide compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Lacosamide. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA216185). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Vimpat. U.S. Food & Drug Administration.
[7]
SEC EDGAR — UCB company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Sodium Channel Alpha Subunit Blocker[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: UCB

Patent Landscape[6]

Patent Cliff

Jun 5, 2040

Earliest patent expiration — generic entry possible after this date

Patent #Expires

11337943Jun 5, 2040

12042474Jun 5, 2040

11883374Jun 5, 2040

Vimpat

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2027

Q4 2027

Trials by Indication[1]

Seizure23 trials

Epilepsy11 trials

Migraine4 trials

Status Epilepticus3 trials

Intravenous3 trials

Diabetic Neuropathy3 trials

CAR2 trials

Neuropathic Pain2 trials

Monotherapy2 trials

Brain Injury2 trials

OSA2 trials

Tics2 trials

Chronic Pancreatitis1 trial

Fibromyalgia1 trial

Osteoarthritis1 trial

Epilepsy Syndrome1 trial

Neuropathy1 trial

Autoimmune Encephalitis1 trial

Partial Epilepsy1 trial

Epileptics1 trial

Pediatrics1 trial

EEG1 trial

Clinical Trial1 trial

Metastasis1 trial

Sciatica1 trial

Fasting Conditions1 trial

Alcohol Use Disorder (AUD)1 trial

Neonatal seizure1 trial

Renal Impairment1 trial

Infusion1 trial

Pregabalin1 trial

Sleep1 trial

Total Hip Arthroplasty1 trial

Major Depressive Episode1 trial

Malignant Glioma1 trial

Oral1 trial

Heavy Drinker1 trial

Transcranial Magnetic Stimulation1 trial

Medication1 trial

Herpes Zoster1 trial

Treatment1 trial

Efficacy1 trial

Trigeminal Neuralgia1 trial

Unspecified1 trial

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Patent Landscape[6]

Related News